Cellares key facts
as of Oct 2026- Operator of an integrated development and manufacturing organization intended for accelerating patients' access to life-saving cell therapies.
- Cellares is valued at approximately $675.0M as of Oct 2026, per PrivateMarketView’s mark.
- It has raised $612.0M across 1 recorded rounds; the latest was Later Stage VC ($82.0M) in Apr 2021.
- Notable investors include 8VC, EDBI, Baillie Gifford, T. Rowe Price Group, Eclipse Capital — 16 tracked in total.
- 1 institutional filer reports fund marks on Cellares across 1 filings.
- Cellares has filed 1 Form D with the SEC, most recently May 2021 ($82.0M sold to 9 investors).
- Status: Privately Held (backing).
Nothing comparable since the round — shown at its later-stage round, Aug 2023 ($675.0M post-money).
- ·The complete investor list: 16 names
- ·Watch Cellares: the Monday email on marks, rounds and moves
Institutional fund marks on Cellares
1 filers · latest Jul 20261 SEC-registered fund reported 1 fair-value mark on Cellares between Jul 2026 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Cellares funding rounds
1 roundsWho backs Cellares
16+Membership and data by Private Market View
Cellares valuation
Cellares is valued at approximately $675 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Aug 2023, at a $675 million post-money valuation.
Recent activity
In the last 90 days, Cellares's record added 1 institutional fund mark (latest period Jul 2026).
How much has Cellares raised?
Cellares has raised $612 million in total; 1 of its rounds is on record. The largest on record was an $82 million later-stage round in Apr 2021.
Cellares has filed 1 Form D with the SEC, most recently in May 2021 ($82 million sold to 9 investors).
Institutional holders and vehicles
1 SEC-registered fund reported 1 fair-value mark on Cellares for Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Cellares investors
16 investors are on record for Cellares, including 8VC, EDBI, Baillie Gifford and T. Rowe Price Group. By type, the record holds 4 venture capital firms, 2 family offices and 2 hedge funds. The later-stage round in Apr 2021 drew 9 investors.
About Cellares
Operator of an integrated development and manufacturing organization intended for accelerating patients' access to life-saving cell therapies. The company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies, enabling academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, and meet global patient demand.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2019
- Employees
- 150
- Website
- cellares.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.